A phase 1 clinical trial of a new cellular immunotherapy being developed in Australia for the treatment of multiple sclerosis (MS) has found that it improved symptoms and quality of life for the majority of patients. …
Latest Video
New Stories
-
Bluebird Bio confirms price of its first gene therapy
June 17, 2019 - - Latest News -
Where will the government find the billions for new listings?
June 17, 2019 - - Latest News -
Will it require another 'Factor F' program?
June 17, 2019 - - Latest News -
PBAC - May 'intracycle' outcomes
June 17, 2019 - - Latest News -
What is the 'opportunity cost' of doing nothing?
June 17, 2019 - - Latest News -
Lack of investment driving back-room deals
June 14, 2019 - - Latest News -
New technologies exposing flaws in HTA
June 14, 2019 - - Latest News